ProCE Banner Series

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-Free Treatment Paradigm

Join us for this interactive, case-based, CME-certified live symposium at ASH 2024 to learn the latest expert perspectives on recently approved and emerging targeted therapies for patients with relapsed/refractory follicular lymphoma. Be sure to bring your questions for the expert panel.

Friday Satellite Symposium preceding the ​66th ASH Annual Meeting and Exposition.

  AMA
Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with relapsed/refractory follicular lymphoma.

All Events

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-Free Treatment Paradigm

Upcoming Events

December

06

2024

11:00 AM - 1:00 PM Pacific Time (PT)

In-person

Manchester Grand Hyatt San Diego, 1 Market Pl., San Diego, California 92101

11:30 AM - 1:00 PM Pacific Time (PT)

Virtual

Faculty

ProCE Banner Faculty
Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

ProCE Banner Faculty
Sonali M. Smith, MD, FASCO

Elmwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Topics

Lymphoma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with relapsed/refractory follicular lymphoma. 

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with relapsed/refractory follicular lymphoma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the therapeutic rationale, as well as efficacy and safety evidence, for emerging therapies in the treatment of patients with relapsed/refractory follicular lymphoma
  • Apply clinical trial evidence, guidelines, and expert recommendations to optimize the selection and sequencing of bispecific antibodies, CAR T-cell therapy, and epigenetic modifiers for patients with relapsed/refractory follicular lymphoma
  • Mitigate and manage adverse events associated with novel treatment regimens in relapsed/refractory follicular lymphoma according to guidelines and expert recommendations
  • Assess patients for equitable enrollment on clinical trials of BTK inhibitors and other novel therapies and combinations for relapsed/refractory follicular lymphoma

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which included participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC in partnership with Follicular Lymphoma Foundation.

Supported by educational grants from AstraZeneca; Genmab US, Inc.; and Ipsen Biopharmaceuticals, Inc.